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Abstract: Multiple myeloma (MM) is a B-cell malignancy characterized by clonal expansion 
of plasma cells within the bone marrow, the presence of a serum and/or urine monoclonal 
protein, lytic bone lesions, and anemia. On a cellular level, the disease is characterized by 
complex interactions between tumor cells and the surrounding bone marrow microenvironment. 
Understanding of the relationship between malignant plasma cells and the microenvironment has 
sparked ongoing efforts to develop targeted therapeutic agents for treatment of this disease. The 
successful development of the first-in-class small-molecule proteasome inhibitor bortezomib 
occurred as a result of these efforts. This review focuses on the rationale for bortezomib therapy 
in the treatment of patients with newly diagnosed and relapsed MM, important treatment-related 
side effects, and future directions for use of bortezomib and other, emerging proteasome 
inhibitors.
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Introduction
Multiple myeloma (MM) is a hematologic malignancy of B-cell origin that constitutes 
approximately 1% of all malignant tumors and 10% to 15% of hematopoietic 
neoplasms.1 In 2008, there were an estimated 19,920 new cases of MM in the United 
States and 10,690 deaths attributable to the disease.2 It primarily occurs in older 
individuals, with an average age at diagnosis of 65,3 and is associated with a number 
of important clinical manifestations including osteolytic bone lesions, renal failure, 
anemia, recurrent infections, neuropathy, and hypercalcemia. For over 40 years, 
corticosteroids and conventional chemotherapy provided the basis for MM therapy 
with such regimens as high-dose dexamethasone;4,5 melphalan and prednisone;6 
and vincristine, doxorubicin, and pulsed high-dose dexamethasone (VAD).7–11 
High-dose therapy and autologous stem cell transplantation (ASCT) in MM was 
pioneered during the 1980s12,13 and has a well established role in the treatment of 
appropriately selected individuals with MM. Over the past decade, though, the therapy 
for MM has changed significantly with the introduction of the immunomodulatory 
drugs (IMiDs) thalidomide and lenalidomide as well as the proteasome inhibitor 
bortezomib. These agents target specific pathways within MM cells and the bone 
marrow microenvironment that have been identified and characterized through 
careful preclinical investigation. This review focuses specifically on the development 
and current applications of the first-in-class proteasome inhibitor bortezomib in the 
treatment of MM.Cancer Management and Research 2009:1 108
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Mechanism of action
The ubiquitin-proteasome pathway plays an important role 
in intracellular protein homeostasis by regulating protein 
degradation. As such, it affects critical cellular processes 
such as cell cycle regulation, antigen processing, and 
apoptosis. Protein degradation occurs through a 2-step 
process in which proteins destined for removal first undergo 
ATP-dependent ubiquitination followed by a second step of 
proteolysis within the 26S proteasome, which consists of a 
proteolytic core, the 20S proteasome, surrounded by two 
19S regulatory complexes.14 The 20S proteasome possesses 
chymotrypsin-like, trypsin-like, and caspase-like catalytic 
activity. Proteasome inhibitors are classified as either 
reversible or irreversible and on the basis of their inhibition 
of chymotrypsin-like, trypsin-like, or caspase-like catalytic 
activity.
Bortezomib is a boronic acid dipeptide small molecule 
that reversibly inhibits the chymotrypsin-like activity of 
the 20S proteasome. The onset of bortezomib’s anti-MM 
activity is rapid, with apoptosis of MM cells occurring 
within several hours after exposure.15 NF-κB is an important 
target of bortezomib within MM cells. Inhibition of NF-κB 
decreases adherence of MM cells to the bone marrow stromal 
cells, thus inhibiting paracrine-mediated growth of MM cells 
and enhancing susceptibility to therapeutic agents.16 While 
inhibition of NF-κB provided the initial rationale for use of 
this agent in MM, it is now understood that bortezomib targets 
a number of other molecules and pathways within MM cells. 
For example, bortezomib-induced apoptosis of MM cells is 
associated with activation of caspase-8/9 and caspase-3.15 
Bortezomib also cleaves DNA repair enzymes, increasing 
the susceptibility of MM cells to classes of DNA-damaging 
agents such as alkylating agents and anthracyclines.17,18 
In addition, the agent induces pro-apoptotic elements of 
the unfolded protein response such as PERK, ATF4, and 
CHOP/GADD153.19,20 Finally, IL-6- induced activation of 
ERK, STAT3, and AKT is inhibited by bortezomib via its 
ability to downregulate gp130.21
In addition to these anti-tumor effects, bortezomib has 
important effects on the development and progression of 
MM-associated bone disease. Bone abnormalities such as 
osteoporosis, compression fractures, and lytic lesions are 
characteristic of MM and are present in approximately 80% of 
patients at the time of diagnosis.22 MM cells secrete osteoclast 
activating factors such as RANKL, IL-3, macrophage 
inflammatory protein, and IL-6, while levels of the RANKL 
decoy receptor osteoprotegrin, which regulates osteoclast 
activity, are decreased in patients with the disease.23 In addition, 
increased levels of osteoblast inhibitors dickhofp-1 (DKK1), 
IL-7, and IL-3 in MM diminish bone anabolism.24 These 
events disrupt the balance of osteoblast and osteoclast function 
in favor of bone catabolism and contribute to the pathogenesis 
of MM-associated bone disease. Bortezomib antagonizes 
these processes in several ways. It decreases levels of RANKL 
and DKK125 and increases levels of alkaline phosphatase and 
osteocalcin, two markers of bone formation.26 In addition, 
bortezomib appears to inhibit osteoclast differentiation27 
and augment osteoblast proliferation by inducing the 
differentiation of mesenchymal stem cells into osteoblasts.28 
The beneficial effects of bortezomib on bone disease in MM 
have also been demonstrated in vivo through studies utilizing 
murine models.29,30
Bortezomib-based treatment 
strategies
Relapsed MM
The significant anti-MM activity of bortezomib observed 
in preclinical studies provided the impetus for subsequent 
clinical development of the drug. Phase I and II studies 
involving patients with relapsed MM demonstrated a 
manageable toxicity profile and confirmed the activity of 
bortezomib in this setting.31–33 These efforts culminated 
in the international, multicenter phase III Assessment of 
Proteasome Inhibtion for Extending Remissions (APEX) 
trial, in which 669 patients with relapsed MM, more than 
50% of whom had undergone two or more prior lines of 
therapy, were randomized to receive either bortezomib 
1.3 mg/m2 on days 1, 4, 8, and 11 of each 21-day cycle 
for eight 3-week cycles, followed by treatment on days 1, 
8, 15, and 22 for four 5-week cycles; or dexamethasone 
40 mg on days 1–4, 9–12, 17–20 for four 5-week cycles, 
followed by treatment on days 1–4 for five 4-week cycles.34 
Bortezomib was superior to high-dose dexamethasone 
for overall response (OR) rate (38% vs 18%), complete 
response (CR) rate (6% vs 1%), median time to progression 
(TTP) (6.22 vs 3.49 months), and 1-year overall survival 
(OS) (80% vs 66%). Grade 3/4 treatment-related toxicities 
included thrombocytopenia (26%), neutropenia (14%), 
anemia (10%), peripheral neuropathy (7%), and diarrhea 
(7%). With extended follow up of APEX participants, the OR 
and CR rates among bortezomib-treated patients improved 
to 43% and 9%, respectively,35 while the median OS was 
29.8 months in the bortezomib arm compared to 23.7 months 
in the dexamethasone arm.
Demonstration in preclinical studies of synergy between 
bortezomib and other classes of agents such as corticosteroids, Cancer Management and Research 2009:1 109
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alkylating agents, and anthracyclines prompted evaluation of 
bortezomib-based combinations.15,17,36 In the phase II Study 
of Uncontrolled Myeloma Management with proteasome 
Inhibition Therapy (SUMMIT) and Clinical Response and 
Efficacy Study of bortezomib in the Treatment of refractory 
myeloma (CREST) trials, patients with progressive dis-
ease after two cycles or stable disease after four cycles 
could receive oral dexamethasone 20 mg on the day of and 
day after bortezomib. In the SUMMIT trial, 13 (18%) of 
78 patients with stable or progressive disease after several 
cycles of bortezomib monotherapy achieved a minimal or 
partial response with the combination.32 Among CREST 
study participants, the OR rate among those who received 
the combination was 50%.33
As predicted by preclinical models, combinations 
including bortezomib and anthracyclines have also been 
effective in relapsed and refractory MM. In a randomized, 
phase III trial involving 646 individuals with relapsed 
and refractory disease, 66% of whom had received two or 
more prior lines of therapy, treatment with bortezomib plus 
liposomal doxorubicin was superior to bortezomib alone 
in terms of median TTP (9.3 vs 6.5 months) and 15 month 
OS (76% vs 65%).37 Although grade 3/4 toxicities such as 
anorexia, vomiting, thrombocytopenia, neutropenia, and 
hand-foot syndrome occurred more frequently with the 
doublet, cardiac toxicity was only minimally increased 
with the combination and rates of peripheral neuropathy 
(PN) were nearly equivalent. In a phase II study involving 
64 heavily pretreated patients with relapsed and refractory 
MM, bortezomib, doxorubicin, and dexamethasone (PAD) 
produced a partial response (PR) or better in 67% and a very 
good partial response (VGPR) or better in 25%.38 Frequent 
grade 3/4 toxicities included thrombocytopenia, neutropenia, 
infection, and peripheral neuropathy, and two patients 
experienced grade 3/4 congestive heart failure.
In addition to its sensitizing effect on corticosteroids 
and conventional classes of chemotherapeutic agents such 
as anthracyclines, bortezomib exhibits significant activity 
in combination with other novel agents in the treatment of 
relapsed and refractory MM. In a phase I/II study, bortezomib 
and thalidomide were administered to 85 patients with 
relapsed and refractory MM.39 The dose range of bortezomib 
was 1.0–1.3 mg/m2 on days 1, 4, 8, and 11, while thalidomide 
was given starting with cycle two at doses of 50–200 mg/day. 
Dexamethasone 20 mg on the day of and day after bortezomib 
was added during cycle four for patients with less than a PR. 
A minor response (MR) or better occurred in 79% of study 
participants, while 63% achieved a PR or better. The most 
common grade 3/4 toxicities included thrombocytopenia 
and neutropenia. Although the cumulative incidence of PN 
with this combination has been approximately 60%, grade 
3/4 PN has been infrequent and the neuropathy has, in many 
instances, been reversible.
Bortezomib plus lenalidomide, and dexamethasone 
(RVD) is also very active in relapsed and refractory MM. 
The rationale for this approach is derived from preclinical 
work demonstrating dual apoptotic signaling, with in vitro 
modeling suggesting the synergistic tumoricidal activity of 
bortezomib and lenalidomide.40 In a phase II study, 64 patients 
with relapsed and refractory MM who had received 1–3 prior 
lines of therapy received bortezomib 1.0 mg/m2 days 1, 4, 8, 
and 11; lenalidomide 15 mg days 1–14, and dexamethasone 
40 mg (cycles 1–4) or 20 mg (cycles 5–8) on days of, and 
after, bortezomib for up to eight 21-day cycles.41 To date, 
the rate of MR or better in this study is 86%, with 24% of 
study participants achieving a CR/near CR (nCR) and 67% 
achieving a PR or better. Among patients who respond to 
therapy, the median duration of response (DOR) has been 
21 weeks. Importantly, response rates have been equivalent 
among patients with standard risk features and those with 
high-risk disease characterized by advanced ISS stage and 
cytogenetic abnormalities. Toxicities have included grade 
1–2 myelosuppression and two cases of deep vein throm-
bosis (DVT).
Newly diagnosed MM
Bortezomib has also proven effective in the treatment of 
patients with newly diagnosed MM on the basis of numerous 
clinical trials involving patients who are eligible for ASCT 
and those who are not. In a large, multicenter phase III 
trial involving 682 ASCT-ineligible patients with newly 
diagnosed MM, bortezomib plus melphalan and prednisone 
(VMP) was compared to MP alone.42 All patients received 
melphalan 9 mg/m2 and prednisone 60 mg/m2 days 1–4 of 
each 6-week cycle, while bortezomib was administered in 
the VMP arm at 1.3 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, 
and 32 during cycles 1–4 and on days 1, 8, 22, and 29 during 
cycles 5–9. VMP was superior to MP in terms of the study’s 
primary endpoint of TTP (24 vs 16.6 months), as well as 
secondary endpoints CR rate (30% vs 4%) and DOR (19.9 
vs 13.1 months). The hazard ratio for survival favored VMP 
to MP (0.61). Grade 3 toxicities were more common with 
VMP than MP (53% vs 44%), while grade 4 toxicities were 
equivalent (28% vs 27%). 13% of participants in the VMP 
arm experienced grade 3 PN, while one patient developed 
grade 4 PN.Cancer Management and Research 2009:1 110
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A variety of bortezomib-based combinations have been 
utilized in the upfront treatment of individuals eligible for 
ASCT. In one of the largest of these trials, 480 patients 
with newly diagnosed MM were randomized to either 
VAD or bortezomib plus dexamethasone induction.43 This 
was followed by a second randomization to two cycles of 
dexamethasone, cyclophosphamide, etoposide, platinum 
(DCEP), consolidation or not, prior to ASCT. In preliminary 
analysis, bortezomib plus dexamethasone was superior to 
VAD induction with respect to rates of VGPR or better 
(46.7% vs 18.6%) and CR/nCR (21.3% vs 8.3%), even 
among patients with an advanced ISS score and del(13). 
Importantly, the benefit of bortezomib-based induction in 
this trial persisted post-ASCT with respect to both VGPR 
or better (40.8% vs 28.8%) and CR/nCR (71.8% vs 51%). 
DCEP consolidation did not improve response rates in either 
treatment group. Although treatment-related PN occurred 
more frequently with bortezomib plus dexamethasone 
induction, the overall rate of therapy-related toxicities was 
equivalent. Stem cell collection was successful in 97% of 
patients who received bortezomib plus dexamethasone and 
99% of those who received VAD.
In another large, phase III trial, 480 transplant-eligible 
patients with newly diagnosed MM were randomized to 
bortezomib plus thalidomide and dexamethasone (VTD) or 
thalidomide and dexamethasone (TD) alone. Patients in the 
TD arm received thalidomide 200 mg daily for days 1–63 
with dexamethasone 40 mg daily on days 1–4 and 9–12 of 
each 21-day cycle. Patients in the VTD arm received the same 
dose/schedule of thalidomide, with bortezomib 1.3 mg/m2 
on days 1, 4, 8, and 11 of each cycle and dexamethasone 
40 mg on the day of, and after, each dose of bortezomib.44 
Preliminary analysis presented at the 2008 American Society 
of Hematology (ASH) meeting demonstrated the superiority 
of VTD in comparison to TD with respect to OR rate (92% 
vs 78.5%), CR/ nCR rate (33% vs 12%), and VGPR or better 
(61% vs 30%). While the rate of  grade 3 PN was higher 
in the VTD arm (9% vs 2.5%), the overall rate of serious 
adverse events was similar. A sufficient number of stem 
cells for up to two ASCT were collected in 91% of patients 
in the VTD group and 87% in the TD arm. Among patients 
who underwent ASCT, those who received VTD did better 
in terms of VGPR or better (75% vs 53%), CR/nCR (54% 
vs 29%), and CR rate (41% vs 20%). After 15 months of 
follow-up, progression-free survival (PFS) was superior 
among study participants who received VTD (93% vs 86%), 
while the 20-month overall survival rate was equivalent in 
the two arms.
In the phase III HOVON-65/GMMG-HD4 study, 
preliminary results of which were also presented at the 2008 
ASH annual meeting, 833 transplant-eligible patients with 
newly diagnosed MM were randomized to either VAD or 
PAD induction followed by stem cell mobilization and either 
single or tandem ASCT.45 This was followed by maintenance 
therapy with either thalidomide 50 mg daily (VAD arm) or 
bortezomib 1.3 mg/m2 every 2 weeks (PAD arm) for 2 years. 
In a preliminary analysis, PAD induction proved superior 
to VAD with respect to rates of OR (80% vs 64%), VGPR 
or better (41% vs 17%), and CR (5% vs 0%). The benefit 
of PAD over VAD induction persisted post-transplant, with 
superior OR (92% vs 77%) and CR (15% vs 4%) rates. In this 
initial analysis, bortezomib maintenance further improved the 
CR/nCR rate from 23% to 35%, suggesting that additional 
bortezomib-based therapy post-transplant deepens the overall 
response to therapy.
RVD is also highly effective as initial therapy for both 
transplant-eligible and transplant ineligible patients with newly 
diagnosed MM. In a phase I/II study of this combination, 
68 patients have received the combination to date, 33 as 
part of the phase I dose-escalation phase and 35 in the 
phase II phase utilizing the maximum tolerated dose (MTD) 
of lenalidomide 25 mg and bortezomib 1.3 mg/m2.46,47 The 
OR rate is 100%, with 74% of patients achieving a VGPR 
or better and 44% achieving a CR/nCR. Among patients 
who received the MTD, the OR rate was 100%. It is notable 
that rates of response were not affected by such adverse 
prognostic features as del(13) and t(4; 14). Moreover, the 
regimen was well-tolerated, with low rates of both DVT/
pulmonary embolism (5%) and grade  3 PN (3%).
Bortezomib-based therapy  
in unique patient populations
Coupled with advances in translational science, rapid drug 
development in MM has substantially expanded treatment 
options for patients. This is underscored by the most recent 
guidelines on MM therapy from the National Comprehensive 
Cancer Network (NCCN), which include multiple treatment 
regimens for both relapsed and refractory disease and newly 
diagnosed MM.48 Various factors are considered in decisions 
on appropriate therapy for an individual patient, including the 
clinical/biological features of a patient’s disease, comorbid 
conditions, and mode of drug administration. Clinical 
experience with bortezomib indicates there are certain patients 
in whom the agent appears to confer unique benefits.
Bortezomib appears to overcome the poor prognosis 
associated with an elevated Β2-microglobulin49 and with Cancer Management and Research 2009:1 111
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chromosomal abnormalities such as 13q deletion and 
t(4; 14).49–52 The agent is thus an important component of 
therapy for individuals with high-risk MM on the basis of 
these prognostic factors. Bortezomib has also proven effective 
in the management of MM patients with renal dysfunction, 
a common manifestation of the disease noted at the time of 
diagnosis in approximately 30% of individuals.22,53 Based 
on the results of a case series involving MM patients with 
dialysis-requiring renal failure at the time of bortezomib 
therapy, the agent yields OR and CR rates in this population 
that are comparable to those seen among individuals without 
renal failure.54 Moreover, four patients in this series became 
dialysis-independent as a result of bortezomib therapy. 
As discussed previously, bortezomib therapy is beneficial for 
individuals with significant disease-related bone disease due 
to its inhibitory effect on osteoclastogenesis27 and stimulatory 
effect on osteoblast differentiation and proliferation.28 
Finally, MM patients with associated AL amyloidosis can 
be considered for bortezomib-based therapy on the basis 
of preliminary evidence of its efficacy in this setting. In a 
retrospective analysis of 20 patients with previously treated 
systemic AL amyloidosis who received bortezomib on 
a standard treatment schedule, 16 responded,55 with 
amyloidotic organ function improved in 6 of the 16 patients 
who responded to therapy.
Treatment-related side effects
Optimization of therapeutic benefit with bortezomib use 
requires familiarity with, and appropriate management of, 
treatment-related side effects associated with the agent. 
Fatigue, diarrhea, PN, thrombocytopenia, and herpes zoster 
reactivation are among those that are monitored throughout 
the course of therapy.
Peripheral neuropathy
Initial symptoms associated with bortezomib-induced PN 
include pain involving the distal extremities along with 
sensory dysfunction resulting from small-fiber axonal injury. 
With progression of PN, proprioceptive loss, distal weakness 
of the upper and lower extremities, and suppression of deep 
tendon reflexes may occur.56,57 Among 256 patients enrolled in 
the phase II SUMMIT and CREST trials, 90 (35%) developed 
treatment-emergent PN or exacerbation of pre-existing PN.58 
The incidence of PN was dose-related, occurring more 
frequently at the 1.3 mg/m2 dose than 1.0 mg/m2, and peaked 
at cycle 5 with a cumulative dose of approximately 30 mg/m2. 
While the rate of bortezomib-associated PN was similar 
among patients with and without baseline PN, patients with 
pre-existing PN experienced more severe treatment-related 
symptoms. One or more courses of therapy was withheld as 
a result of treatment-associated PN in 19/90 (21%) patients, 
while dose reduction or discontinuation were required in 
12% and 5%, respectively. Bortezomib-associated PN is 
reversible with treatment interruption in the majority of 
patients.58,59 Indeed, among SUMMIT and CREST study 
participants, symptoms improved to baseline in 71% of those 
who experienced  grade 3 treatment-associated PN.
Various measures can be employed to prevent bortezomib-
induced PN and manage symptoms when PN occurs. 
Alpha-lipoic acid, an organosulfur enzyme cofactor that 
possesses antioxidant properties and modulates glucose 
uptake, has been used for prevention of diabetic peripheral 
neuropathy and may be beneficial for MM patients who 
receive bortezomib, although this intervention requires 
further study in bortezomib-treated MM patients.60 Similarly, 
acetyl-L-carnitine, an ammonium-containing compound 
derived from the amino acids methionine and lysine, 
has antioxidant and neurotrophic activity and appears 
to ameliorate chemotherapy-induced PN.61 In addition, 
the regular application of thick emollients enriched with 
antioxidants and putative neurotransmitters, such as cocoa 
butter or topical menthol-containing preparations,62 appears 
to benefit patients receiving bortezomib, perhaps by 
enhancing small fiber function and recovery. There is solid 
clinical rationale for these interventions, although prospective 
studies are needed to validate their efficacy in the context of 
bortezomib-based MM therapy.
Despite such strategies aimed at limiting the development 
or progression of bortezomib-induced PN, a significant 
number of MM patients require additional intervention. 
A prospective algorithm for bortezomib dose reductions 
as was derived from the SUMMIT and CREST trials and 
applied in the APEX study is recommended for individuals 
who receive the agent (Table 1).34 Patients with pain 
or severe paresthesias may require symptom-directed 
pharmacotherapy. Options that have proven effective in 
this respect include the anticonvulsants gabapentin and 
pregabalin; serotonin-norepinephrine reuptake inhibitors 
such as duloxetine; tricyclic antidepressants amitriyptyline 
and desipramine; and opioids such as oxycodone, morphine 
sulfate, and hydrocodone.63
Thrombocytopenia
In the SUMMIT and CREST trials, therapy-associated 
thrombocytopenia occurred in 42% of study participants, 
and was the most frequently reported grade 3 adverse event.64 Cancer Management and Research 2009:1 112
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Grade 3/4 thrombocytopenia was noted in 30% of study 
participants overall but importantly was uncommon (13%) 
in individuals with a baseline platelet count 200 × 109/L. 
Indeed, there was an inverse correlation between baseline 
platelet count and the incidence of grade 3/4 thrombocytopenia. 
Bleeding episodes associated with bortezomib-induced 
thrombocytopenia were infrequent, but can occur as a 
complication of therapy, albeit rarely. In one instance, 
gastrointestinal bleeding developed in the setting of grade 3 
thrombocytopenia. In another, grade 1 epistaxis occurred in 
the context of grade 4 thrombocytopenia.
Although the mechanism by which bortezomib induces 
thrombocytopenia is unknown, murine studies suggest that 
it does involve a direct cytotoxic effect on megakaryocytes 
or alteration in thrombopoietin (TPO) levels.64 During a 
standard 21-day treatment cycle, the platelet count typically 
follows a biphasic pattern, with a decline of on average 60% 
of the baseline platelet count during the 11-day period of 
bortezomib administration followed by recovery during the 
rest period.64 The platelet count is thus monitored closely 
during treatment, with platelet transfusions if indicated and 
bortezomib dose reduction for high grade thrombocytopenia 
if it is persistent despite transfusion and if there is a concern 
regarding hemorrhage. The presence of baseline thrombo-
cytopenia and concomitant use of agents known to cause 
myelosuppression – such as anthracyclines, alkylating drugs, 
and lenalidomide – necessitates caution.
Gastrointestinal side effects
Gastrointestinal (GI) side effects associated with bortezomib 
were common among participants in the APEX trial, with 
diarrhea and nausea occurring in 57%, constipation in 
42%, vomiting in 35%, anorexia in 23%, and abdominal 
pain in 16%.34 However, grade 3/4 bortezomib-associated 
GI toxicities were infrequent in this study. Pre-emptive 
supportive care measures are an important component of care 
in the management of MM patients receiving bortezomib. 
Corticosteroids, 5-HT3 receptor antagonists such as 
ondansetron and phenothiazines are effective antiemetics in 
this setting. Stool softeners, laxatives, and antidiarrheals are 
utilized in the management of constipation and/or diarrhea. 
Proton-pump inhibitors and/or H2-receptor blockers 
are employed in patients who, due to prolonged steroid 
use, are prone to gastritis or gastric/duodenal ulceration. 
At our institution, we have also documented GI dysmotility 
based on evaluation of gastric emptying in patients 
receiving bortezomib-based therapy. Promotility agents 
such as metoclopramide can be used in this situation, and 
attention to the avoidance of constipation is important. The 
International Myeloma Foundation (IMF) Nurse Leadership 
Board has also compiled comprehensive guidelines for the 
management of GI side effects in MM patients treated with 
novel therapies.65
Herpes zoster reactivation
Herpes zoster virus (HZV) reactivation within nerve cell 
bodies results in a characteristic painful, vesicular, dermatomal 
rash. It most often occurs in immunocompromised 
individuals, who receive prolonged corticosteroid therapy 
or other immunosuppressive drugs, and among recipients of 
solid-organ or stem cell transplantation.66 MM is associated 
with deficiency in both humoral and cellular immunity,67 
and as such predisposes affected individuals to infection. 
An increased incidence of HZV reactivation among MM 
patients has not been conclusively demonstrated but 
seems very likely based on available data. In the APEX 
trial, however, bortezomib therapy was associated with an 
increased incidence of herpes zoster reactivation as compared 
to high-dose dexamethasone (13% vs 5%, P = 0.0002).34 The 
majority of these infections were grade 1/2 in severity, and 
the incidence of higher grade HZV reactivation was similar 
in the two treatment arms.68 While the biological mechanism 
Table 1 Dose modification guideline for bortezomib-related neuropathic pain and/or peripheral sensory or motor neuropathy10
Severity of peripheral neuropathy signs and symptoms Modification of bortezomib dose and regimen
Grade 1 (paresthesias, weakness and/or loss of reflexes) without pain or loss of function No action
Grade 1 with pain or Grade 2 (interfering with function but not with activities of  
daily living)
Reduce to 1.0 mg/m2
Grade 2 with pain or Grade 3 (interfering with activities of daily living) withhold treatment until toxicity resolves, then reinitiate 
at a dose of 0.7 mg/m2 once weekly
Grade 4 (sensory neuropathy that is disabling or motor neuropathy that  
is life-threatening or leads to paralysis)
Discontinue
Notes: Grading for this currently recommended dose modification guideline is based on National Cancer Institute Common Terminology Criteria for Adverse Events 
(NCI CTCAE) version 3.0. In APEX, the dose modification guideline used was the same, but based on NCI CTC version 2.0 grading; in addition, patients experiencing grade 3 
peripheral neuropathy with pain were to discontinue bortezomib.Cancer Management and Research 2009:1 113
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underlying the apparent association between bortezomib and 
HZV reactivation has not been elucidated, it does not appear 
related to a direct effect of bortezomib on T-cells,69 mature 
lymphocytes,70 or viral replication.71 On the basis of evidence 
from the APEX study as well as our experience in treating 
patients with newly diagnosed disease, we routinely recom-
mend antiviral prophylaxis using an agent such as acyclovir 
or valacyclovir.
Future directions
The successful use of bortezomib in MM has fueled interest in 
novel approaches to the application of this agent as well as in 
the development of new proteasome inhibitors. Combination 
therapy incorporating bortezomib together with emerging 
classes of drugs in MM are a key area of interest. As alluded 
to previously, the anti-MM mechanisms of bortezomib are 
synergistic with those of other drug classes (Figure 1), and 
combination therapy improves response and survival rates 
in comparison to single-agent therapy. In particular, the high 
level of activity observed to date with bortezomib-based 
combinations such as VTD, PAD, and RVD has provided 
the impetus for new approaches to therapy incorporating 
emerging drugs in MM. For example, the combinations of 
bortezomib and the histone deacetylase (HDAC) inhibi-
tor vorinostat,72–74 bortezomib and the heat shock protein 
90 (Hsp90) inhibitor tanespimycin,75 and bortezomib and 
the Akt pathway inhibitor perifosine76 have been evaluated 
in early phase clinical trials involving patients with relapsed 
and/or refractory MM. These regimens have shown promis-
ing anti-MM activity, even among patients who previously 
were refractory to bortezomib, and the respective toxicity 
profiles have been favorable. As additional classes of drugs 
gain a foothold in MM therapy, it will be necessary to deter-
mine the efficacy of certain regimens, but also the sequence 
and schedule by which agents are administered.
Historically, ASCT in MM has served as a means by 
which to increase the depth of response achieved through 
induction therapy. Indeed, ASCT following induction has 
been a standard of care for younger MM patients eligible for 
the procedure and is associated with a PFS advantage as com-
pared to induction therapy alone in this group of patients.77 
Whether induction regimens incorporating bortezomib and 
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Figure 1 Synergistic anti-MM activity of bortezomib in combination with other agents.
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other novel agents, which are associated with unprecedented 
response rates in this disease, will improve the relative benefit 
of ASCT in MM is unknown. That response rates among 
patients who receive bortezomib-based induction improve 
further in the aftermath of ASCT suggests this may be true, 
but the issue needs to be definitively assessed in a randomized 
comparison of novel therapy-based induction with or without 
ASCT consolidation.
The use of bortezomib maintenance therapy following 
ASCT is also an area of considerable interest. The practice 
in MM of post-ASCT maintenance therapy using thalidomide 
has been established on the basis of results from four 
randomized clinical trials that suggest the approach improves 
PFS.78–80 Moreover, results from three of these trials indicate 
that thalidomide maintenance is associated with an OS 
benefit. Caution must be exercised with this approach, 
however, as there is evidence thalidomide maintenance 
after ASCT may be associated with shorter survival times 
following relapse.78,81 Whether post-ASCT maintenance 
with bortezomib, through continued inhibition of the 
proteasome, confers significant clinical benefit is unknown. 
This question is being addressed as part of the previously 
referenced phase III trial led by the HOVON group, in which 
transplant-eligible individuals with newly diagnosed MM 
receive either VAD or PAD induction followed by ASCT 
and subsequently by maintenance thalidomide (in the VAD 
arm) or bortezomib administered every other week (in the 
PAD arm).45 As discussed previously, preliminary results 
indicate that bortezomib maintenance deepens the level 
of response to therapy. Updated analyses of this study are 
awaited with interest.
Finally, novel proteasome inhibitors are being developed 
with the aim of maintaining potent proteasome inhibition 
while modulating toxicity, specifically neurotoxicity, and 
altering bioavailability such that oral administration is 
possible. Two new proteasome inhibitors, carfilzomib 
(PR-171) and salinosporamide (NPI-0052), have to date 
undergone preclinical evaluation and are currently being 
assessed in early phase clinical trials involving MM patients 
with relapsed and/or refractory disease.82–84
Conclusions
As highlighted by this review, both bortezomib alone and in 
particular bortezomib-based combination therapy are important 
treatment options for individuals with newly diagnosed and 
relapsed MM. Bortezomib can be utilized safely in patients 
with renal dysfunction and has unique impact on bone disease 
frequently associated with MM. Moreover, the agent is 
effective in patients considered to have high-risk disease on 
the basis of chromosomal abnormalities and advanced ISS 
stage. The ability to safely and effectively partner bortezomib 
with other agents, both conventional and novel, is especially 
encouraging. In this context, treatment-associated toxicities 
associated with bortezomib are manageable with close moni-
toring and appropriate dose modifications as well as supportive 
care interventions. It is likely that with ongoing translational 
and clinical research efforts, patients with MM will, in the 
future, derive even greater benefit from bortezomib and the 
emerging second-generation proteasome inhibitors.
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